CL2008000987A1 - Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica, - Google Patents
Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica,Info
- Publication number
- CL2008000987A1 CL2008000987A1 CL200800987A CL2008000987A CL2008000987A1 CL 2008000987 A1 CL2008000987 A1 CL 2008000987A1 CL 200800987 A CL200800987 A CL 200800987A CL 2008000987 A CL2008000987 A CL 2008000987A CL 2008000987 A1 CL2008000987 A1 CL 2008000987A1
- Authority
- CL
- Chile
- Prior art keywords
- penoxi
- dietil
- propil
- butil
- amina
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 208000038016 acute inflammation Diseases 0.000 title 1
- 230000006022 acute inflammation Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037976 chronic inflammation Diseases 0.000 title 1
- 230000006020 chronic inflammation Effects 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92196407P | 2007-04-05 | 2007-04-05 | |
| US92578607P | 2007-04-23 | 2007-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008000987A1 true CL2008000987A1 (es) | 2008-08-08 |
Family
ID=39469930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200800987A CL2008000987A1 (es) | 2007-04-05 | 2008-04-04 | Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica, |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7884219B2 (OSRAM) |
| EP (1) | EP2144883A1 (OSRAM) |
| JP (1) | JP2010523559A (OSRAM) |
| AR (1) | AR065896A1 (OSRAM) |
| CA (1) | CA2681864A1 (OSRAM) |
| CL (1) | CL2008000987A1 (OSRAM) |
| PA (1) | PA8775601A1 (OSRAM) |
| PE (1) | PE20090808A1 (OSRAM) |
| TW (1) | TW200900384A (OSRAM) |
| UY (1) | UY31004A1 (OSRAM) |
| WO (1) | WO2008123914A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523559A (ja) * | 2007-04-05 | 2010-07-15 | トランス テック ファーマ，インコーポレイテッド | ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態 |
| EP2470510B1 (en) | 2009-09-30 | 2014-05-14 | TransTech Pharma, LLC | Substituted imidazole derivatives for treatment of alzheimers disease. |
| BR112015007641A8 (pt) * | 2012-10-05 | 2018-04-03 | Vtv Therapeutics Llc | Tratamento da doença de alzheimer branda e moderada |
| US9717710B2 (en) * | 2012-10-05 | 2017-08-01 | Vtv Therapeutics Llc | Treatment of mild and moderate Alzheimer's disease |
| CN103726005A (zh) * | 2012-10-16 | 2014-04-16 | 深圳富泰宏精密工业有限公司 | 珐琅涂层的制造方法及其制品 |
| WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190822A1 (en) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| EP3864008A1 (en) | 2018-10-10 | 2021-08-18 | vTv Therapeutics LLC | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
| WO2020086388A1 (en) | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Glucokinase activator compositions for the treatment of cognitive impairment |
| US11648235B1 (en) | 2022-12-30 | 2023-05-16 | Cantex Pharmaceuticals, Inc. | Treatment of glioblastoma |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026811A1 (en) * | 2003-05-20 | 2005-02-03 | Mjalli Adnan M. M. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| DK1482931T3 (da) * | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
| JP2010523559A (ja) * | 2007-04-05 | 2010-07-15 | トランス テック ファーマ，インコーポレイテッド | ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態 |
-
2008
- 2008-03-12 JP JP2010502079A patent/JP2010523559A/ja active Pending
- 2008-03-12 CA CA002681864A patent/CA2681864A1/en not_active Withdrawn
- 2008-03-12 US US12/046,872 patent/US7884219B2/en active Active
- 2008-03-12 WO PCT/US2008/003325 patent/WO2008123914A1/en not_active Ceased
- 2008-03-12 EP EP08726789A patent/EP2144883A1/en not_active Withdrawn
- 2008-03-19 TW TW097109673A patent/TW200900384A/zh unknown
- 2008-03-31 AR ARP080101342A patent/AR065896A1/es unknown
- 2008-04-04 PE PE2008000616A patent/PE20090808A1/es not_active Application Discontinuation
- 2008-04-04 PA PA20088775601A patent/PA8775601A1/es unknown
- 2008-04-04 UY UY31004A patent/UY31004A1/es not_active Application Discontinuation
- 2008-04-04 CL CL200800987A patent/CL2008000987A1/es unknown
-
2010
- 2010-12-30 US US12/982,775 patent/US8372988B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010523559A (ja) | 2010-07-15 |
| TW200900384A (en) | 2009-01-01 |
| PE20090808A1 (es) | 2009-06-27 |
| US20110166361A1 (en) | 2011-07-07 |
| WO2008123914A1 (en) | 2008-10-16 |
| EP2144883A1 (en) | 2010-01-20 |
| US8372988B2 (en) | 2013-02-12 |
| US7884219B2 (en) | 2011-02-08 |
| AR065896A1 (es) | 2009-07-08 |
| US20080249316A1 (en) | 2008-10-09 |
| UY31004A1 (es) | 2008-11-28 |
| PA8775601A1 (es) | 2009-04-23 |
| CA2681864A1 (en) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008000987A1 (es) | Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica, | |
| EP2768514A4 (en) | LOCALIZED MODULATION OF TISSUES AND CELLS TO IMPROVE THERAPEUTIC EFFECTS INCLUDING RENAL RECURRING | |
| CL2014000296A1 (es) | Compuestos derivados de sulfoxidos de 2-(piperidin-1-il)-dihidrotieno[3,2-d]pirimidina; metodo de preparacion; compuestos intermediarios; y uso para tratar enfermedades inflamatorias o alergicas tales como epoc y asma. | |
| WO2013151668A3 (en) | Modified polynucleotides for the production of secreted proteins | |
| HK1206612A1 (en) | Modified polynucleotides for the production of secreted proteins | |
| EP2350110A4 (en) | NEW STEVIOLGLYKOSIDE | |
| BR112012002578A2 (pt) | composição para o tratamento da fibrose cística | |
| CO6940374A2 (es) | Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas | |
| DK2510150T3 (da) | Hidtil ukendt fremgangsmåde til behandling af lignocelluloseholdigt materiale | |
| DK3088512T3 (da) | Anvendelse af moderkage-stamceller til behandling af hjerte- og kredsløbssygdomme ved at fremme angiogenese | |
| PL2797416T3 (pl) | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek | |
| BR112014012539A2 (pt) | moléculas de ligação específicas para her3 e usos dessas | |
| DK2318396T5 (da) | Krystalform af posaconazol | |
| ITTO20110627A1 (it) | Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche | |
| BR112013017669A2 (pt) | di-hidrofuranos fundidos como moduladores de gpr119 para o tratamento de diabetes, obesidade e doenças relacionadas | |
| BRPI0914614A2 (pt) | 2-arilaminoquinazolinas para tratar doenças proliferativas | |
| BRPI0919327A2 (pt) | compostos ligados a enxofre para tratar doenças e distúrbios oftálmicos | |
| BR302013001868S1 (pt) | Configuração aplicada em aparelho para reprodução de sons | |
| BRPI1005380A2 (pt) | colírio com difluprednato para tratar edema macular, e uso de difluprednato para produzir o dito colírio | |
| BR112013008528A2 (pt) | métodos para tratar psoríase | |
| PL2919796T3 (pl) | Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych | |
| EP2247297A4 (en) | THERAPEUTIC TREATMENT OF LUNG DISEASES | |
| BR112013015048A2 (pt) | composição para o tratamento de distúrbios metabólicos | |
| FR2985183B1 (fr) | Composition cosmetique et dermatologique revitalisante | |
| EP2649206A4 (en) | FORECAST AND TREATMENT OF DIABETES ASSOCIATED COMPLICATIONS |